of a homograft reaction oii the part of the genetically iiicompatible host. The Bergen A4 ascites carcinoma (Hartveit, 1964) (Hartveit, 1965a) have, with one exception (Willheim and Ivy, 1959) , used either transplanted mouse tumours growing as homografts or cells in tissue culture (Bolande, 1960) . In iio case has a tumour transplanted to a geiieticallv compatible host beeii used. The following experiments were therefore carried out on such a tumour, the Bergen A4 ascites carcinoma, to see whether the cells were seiisitised or iiot. Firstly, the reactioii of these tumour cells to fresli human serum w'as compared to that of Ehrlich ascites carcinoma cells, ai-id secoiidly, fresh humaii serum was adsorbed with Bergeii A4 ascites carcinoma cells to see if the cells lArere capable of adsorbing the oncolytic and haemolytic activity, i.e. complemeilt (Hartveit, 1965a) There are, however, two possibilities that must be considered that would result in an antigenic difference between host and tumour in this system. Firstly, a mutation may have occurred in the tumour during its serial transplantatioii. However, such mutations usually take the form of loss rather than gain in antigenicity (Hauschka and Amos, 1957) , and loss of antigenicity would be of no account in this connection. In addition this tumour showed evidence of antigenic difference from its host as early as its third transplant generation (Hartveit, 1964) (see Hartveit, 1964, re Klein, 1951) . In addition preliminarv tests of the action of fresh human serum were carried out oii the first ascitic generation (4th transplaiit geiieration) of this tumour and these tests also showed lysis.
If the findings in experiment I cannot be explained on the basis of antibody supplied by the host in response to an antigenic difference between host and tumour, oiie would have to postulate that the lytic activity of the hiiman serum on Bergen A4 ascites careiiioma cells is due to the presence of heteropbil antibody in the human serum. Now with the Ehrlich ascites carcinoma system it has been shown that this is not so (Hartveit, 1965b) ; the lytic action of human serum in that system is due to its complement content alone. It would be a remarkable coincidence if the variation in complement content of the different sera shown, expressed as the oncolytic ability of the sera, in Fig. 1 
